Record revenue, but the margin math doesn't support the passthrough claim

The headline reads like a blowout. Q1 revenue ₹300.5 crore crosses a historic milestone, management raised EBITDA per kg guidance to ₹44–45, and the pharma segment is firing on all cylinders at +41% YoY growth. Yet the stock opened down 5%, and by day 3 sat -2.6% from the announcement. That gap between optics and market verdict is where the quarter's real story sits.

On the call, management stated multiple times that raw material cost increases had been successfully passed on to all customers. The numbers tell a different story. Gross margin fell 530 basis points quarter-on-quarter, from 46.6% to 41.3%, despite revenue climbing 26.3%. At constant RM cost and no price movement, that would be a disaster. At constant RM cost AND price hikes, it signals one of two things: either (1) customers absorbed the inflation and margin was compressed anyway, or (2) the mix shift into lower-margin segments was severe enough to overcome stated price gains. The call data points to both.

The pivot to EBITDA per kg is management's way of sidestepping the gross margin question. It's not dishonest—the ₹46.7 number is real, the efficiency gains from Hyderabad consolidation (5 units collapsed to 2) are permanent, and the per-unit economics did improve. But at the gross-profit line, customers held the line on cost absorption. That's a material loss of pricing power, especially for a company that built its franchise on premium IML (in-mold label) technology in paint and specialty pharma segments where price leverage should matter.

The 6% volume growth is a second red flag. It's driven by lubes falling 17% due to Iran base oil unavailability—a geopolitical shock, not operational—but the bigger worry is Qpack (edible oil packaging), which grew only 2% despite management's prior +20% momentum. Qpack is price-sensitive; when raw material spiked from ₹97 to ₹130 per kg (35% YoY), edible oil and cashew processors destocked and pushed back on costs. Pharma (+38%) and food (+24%) are offsets, but they're smaller by volume. Lube is expected to recover in Q2–Q3 as geopolitical tensions ease, but Qpack weakness may persist if customer demand stays soft. Management targets 10–12% full-year volume; absent a sharp lube rebound, that's now likely to miss.

Before the bears pile on: pharma is a legitimate growth story. Q1 ₹8–9 crore at +41% YoY, with 20–25 active customers already in book and 10 more visiting in coming weeks, is concrete pipeline—not guidance theatre. The ₹50–55 crore FY27 target (₹34 Cr in FY26) implies a 50% CAGR through the year, and the Q1 data supports it. The device expansion—dosing pens, ophthalmic containers, semiconductor trays—carries 1–3 year development timelines and potential EBITDA per kg of ₹150–200 (vs ₹46.7 today), a structural margin inflection if it lands. Hyderabad consolidation is permanent; the overhead saves and logistics gains won't reverse. And the IML penetration (75.8% of volume, 77.8% of value) is a structural trend supporting mix upgrade in paint and FMCG. On a 5–10 year view, the franchise has real tailwinds.

Gross margin compression that management can't own (they blame RM, but the data says customer absorption) is a credibility dent. Volume growth at 6% YTD vs a 10–12% full-year target is materially behind, with only a lube rebound to count on—a geopolitical roll of the dice. Qpack weakness (from +20% to +2%) is unexplained and could be structural. Working capital jumped ₹15 crore to ₹125 crore due to RM inventory stress; finance cost surged 20% QoQ. If crude prices stay elevated, that burden will persist through FY27, eating into reinvestment and dividend capacity. And the device capex (₹25–30 crore of the ₹90 crore total) is unproven: dosing pens are 1–3 years out, ophthalmic is 6 months to mold completion, semiconductor is a 'very long shot.' That's a heavy R&D bet on timelines that often slip.

The market's verdict was immediate: -5.06% on day 1, fading to -2.58% by day 3. That's a sell-first, ask-questions-later reaction—driven less by the headline revenue beat and more by the gross margin collapse and unmet volume guidance. Volume has increased into the sell-off, suggesting both retail and institutional trimming. FII ownership fell 67 basis points to 9.69% in the most recent quarter (QoQ), marking three consecutive quarters of FII outflows from 10.36% two quarters ago. DII stepped up 83bp to 20.95%, suggesting domestic passive/defensive buying, but FII's trim is notable. Promoters are steady at 33.19%, with only 12bp upside QoQ. The stock sits ₹671.1, down 17.66% from its all-time high of ₹815, but still 44.35% off its 52-week low of ₹464.9. It's trading below its 20-day (₹685.76) and 50-day (₹691.37) simple moving averages, but above its 200-day (₹620.05). RSI of 48.5 signals no oversold bounce imminent. The valuation (not explicitly provided, but implied from the forward context) offers no margin of safety if guidance misses or timelines slip further.

That post-result move is actually instructive: the market is pricing in skepticism on (1) near-term margin recovery, (2) volume guidance credibility, and (3) the size and timing of the device capex bet. It's not a panic sell (the stock didn't crater 10%+), but it's a clear signal that investors don't believe management's passthrough narrative and want proof of execution before re-engaging.